Point-of-Care Testing (POCT) Market Size & Growth Forecast 2027–2036, By Segments (Prescription, End-use, Application, Technology, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Point-of-Care Testing Market size was worth USD 47.36 Billion in 2026 and is expected to grow at 7.42% CAGR between 2027 and 2036, crossing USD 96.89 Billion by 2036. The industry revenue for 2027 is calculated at USD 50.34 Billion.
Get more details on this report
Request Free Sample ReportPoint-of-Care Testing (POCT) Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 36.07% of the market in 2026, supported by sophisticated healthcare infrastructure and widespread adoption of decentralized diagnostic technologies.
- Expanding healthcare access, diagnostic infrastructure investment, rising screening needs, and greater emphasis on early diagnosis are accelerating decentralized testing adoption.
Segment Momentum
- OTC testing captured 59.23% of the market in 2026 and is the fastest-growing prescription segment because it offers convenient, rapid, and accessible diagnostics that support routine screening, early detection, and self-directed healthcare.
- Infectious disease testing is the fastest-growing application as demand rises for rapid detection, decentralized diagnostics, early intervention, and improved public health preparedness through advanced point-of-care testing technologies.
Market Expansion Drivers
- Rising disease burden in developing regions driving demand for rapid diagnostics
- Expanding diagnostic infrastructure increasing adoption of decentralized testing solutions
- Advancements in portable biosensor technologies enabling faster bedside diagnostics adoption
Leading Market Participants
- Key players in the point-of-care testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (United States), Becton, Dickinson and Company (United States), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (United States), Sysmex Corporation (Japan), QuidelOrtho Corporation (United States), Nova Biomedical Corporation (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 47.36 Billion
- 2027 Estimated Market Size: USD 50.34 Billion
- Projected Market Size: USD 96.89 Billion by 2036
- Growth Forecast: 7.42% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: OTC Testing (Prescription) | Diagnostic Centers (End-use) | Cardio Metabolic Testing (Application) | Lateral Flow Assays (Technology) | Glucose Monitoring (Product)
- Emerging Opportunity Segment: OTC Testing (Prescription) | Home-care Settings (End-use) | Infectious Disease Testing (Application) | Molecular Diagnostics (Technology) | Infectious Disease Testing Products (Product)
Market Growth Drivers and Industry Trends
Rising disease burden in developing regions driving demand for rapid diagnostics
Increasing prevalence of infectious and chronic diseases in developing regions is creating a stronger need for accessible diagnostic solutions that deliver immediate results. The point-of-care testing market growth is driven by healthcare providers seeking faster detection methods that can support timely treatment decisions, especially in areas with limited laboratory infrastructure. Portable testing options enable screening closer to patients, reducing dependence on centralized facilities and improving access to essential diagnostic services.
Expanding diagnostic infrastructure increasing adoption of decentralized testing solutions
Healthcare networks are expanding diagnostic capabilities beyond traditional laboratories, encouraging greater use of decentralized testing approaches. As investments in clinics, community health centers, and remote care facilities increase, the point-of-care testing market will drive adoption of solutions that enable efficient testing at patient locations. These systems help healthcare professionals streamline workflows by reducing sample transportation requirements and allowing quicker clinical responses across different care settings.
Advancements in portable biosensor technologies enabling faster bedside diagnostics adoption
Continuous improvements in biosensor accuracy, miniaturization, and device integration are enhancing the performance of bedside diagnostic platforms. The point-of-care testing market demand is boosted by technological developments that allow compact systems to deliver rapid and reliable results with simpler operation. Enhanced sensor capabilities are supporting applications across multiple diagnostic areas, enabling healthcare professionals to perform tests closer to patients while maintaining improved efficiency in clinical decision-making.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising disease burden in developing regions driving demand for rapid diagnostics | 2.3% | High | Asia Pacific, Africa | High | Near Term |
| Expanding diagnostic infrastructure increasing adoption of decentralized testing solutions | 2% | High | North America, Asia Pacific | High | Near Term |
| Advancements in portable biosensor technologies enabling faster bedside diagnostics adoption | 1.7% | High | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for a 36.07% share of the point-of-care testing (POCT) market in 2026, making it the largest regional market. Its leadership is supported by sophisticated healthcare infrastructure, broad adoption of decentralized diagnostic technologies, and strong demand for rapid clinical decision-making. Hospitals, clinics, and other healthcare settings increasingly rely on point-of-care testing to obtain timely diagnostic information and improve patient management. Growing emphasis on preventive care, chronic disease monitoring, and efficient healthcare delivery is further encouraging the use of rapid diagnostic platforms. Continued integration of technologically advanced testing solutions into routine clinical workflows is expected to support regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to be the fastest-growing regional market for point-of-care testing (POCT), supported by expanding healthcare access, rising disease-screening needs, and increasing investment in diagnostic infrastructure. The growing healthcare requirements of large and increasingly urbanized populations are encouraging the adoption of testing solutions that can deliver results closer to patients. Improvements in medical facilities across emerging economies and greater emphasis on early diagnosis are creating additional opportunities for decentralized testing. The need to improve diagnostic accessibility and healthcare efficiency is expected to drive continued adoption throughout the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Decentralized DiagnosticsThe U.S. point-of-care testing (POCT) market prioritizes rapid diagnostic solutions that improve clinical decision-making across hospitals, physician offices, and retail healthcare settings. Healthcare providers increasingly adopt connected testing platforms that enhance workflow efficiency and timely patient management.
Germany 🇩🇪
Clinical Workflow IntegrationGermany emphasizes point-of-care testing solutions that integrate seamlessly into hospital and outpatient diagnostic workflows. Demand is centered on reliable, high-quality testing systems that support faster diagnosis while maintaining stringent clinical performance standards.
Japan 🇯🇵
Aging Care DiagnosticsJapan expands the use of point-of-care testing to support an aging population and improve access to timely diagnostics. Healthcare facilities increasingly value compact, accurate testing platforms that enable efficient monitoring in both clinical and community care environments.
South Korea 🇰🇷
Digital Testing AdoptionSouth Korea advances the point-of-care testing market through digital healthcare integration and demand for rapid diagnostic capabilities. Healthcare providers increasingly adopt connected POCT systems that simplify data management while supporting efficient patient care across diverse settings.
France 🇫🇷
Accessible Diagnostic ServicesFrance focuses on expanding point-of-care testing across hospitals and primary care to improve diagnostic accessibility and treatment efficiency. Clinical adoption favors user-friendly platforms that deliver dependable results while supporting standardized healthcare practices.
Italy 🇮🇹
Regional Care SupportItaly utilizes point-of-care testing to strengthen diagnostic services across hospitals and regional healthcare facilities. Demand reflects growing interest in portable testing systems that reduce turnaround times and improve routine clinical decision-making.
Segment Leadership and Growth Trends
Point-of-Care Testing (POCT) Market Share (%), by Prescription, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportPrescription Segment Analysis: OTC Testing (Largest & Fastest-Growing Segment)
The point-of-care testing market was led by the OTC testing segment, which accounted for 59.23% in 2026, and it is also the fastest-growing prescription category. The segment's leadership is driven by growing consumer preference for convenient, rapid, and accessible diagnostic solutions that can be used without a physician's prescription. OTC testing enables individuals to monitor health conditions quickly while reducing dependence on traditional clinical settings, making it particularly attractive for routine screening and early disease detection. Increasing health awareness, expanding availability of user-friendly testing kits, and the shift toward self-directed healthcare continue to strengthen the segment's market position.
End-use Segment Analysis: Diagnostic Centers (Largest Segment) vs Home-care Settings (Fastest-Growing Segment)
The diagnostic centers segment dominated the point-of-care testing market, accounting for 38.45% in 2026. These facilities remain key providers of rapid diagnostic services due to their specialized infrastructure, trained personnel, and ability to deliver accurate test results with minimal turnaround time. Diagnostic centers also support a broad range of screening and disease monitoring applications, making them an essential component of decentralized healthcare delivery. Growing demand for timely diagnosis and efficient patient management continues to reinforce the segment's leading position.
The home-care settings segment is expected to witness the fastest growth as healthcare increasingly shifts toward patient-centered and remote care models. Rising adoption of easy-to-use diagnostic devices, expanding awareness of preventive healthcare, and growing demand for convenient testing outside conventional healthcare facilities are accelerating product adoption. Advances in portable testing technologies and digital health integration are further supporting the expansion of point-of-care testing within home environments.
Application Segment Analysis: Cardio Metabolic Testing (Largest Segment) vs Infectious Disease Testing (Fastest-Growing Segment)
Holding the largest share of the point-of-care testing market, the cardio metabolic testing segment accounted for 24.19% in 2026. The segment's dominance is supported by the growing burden of cardiovascular and metabolic disorders that require regular monitoring for effective disease management. Point-of-care diagnostic solutions enable rapid assessment of key health indicators, facilitating timely clinical decisions and improving patient outcomes. Increasing emphasis on preventive healthcare and chronic disease management continues to sustain demand for cardio metabolic testing.
The infectious disease testing segment is anticipated to register the fastest growth due to the increasing need for rapid detection and timely management of communicable diseases. Healthcare providers are placing greater emphasis on decentralized diagnostic capabilities that enable early intervention and help limit disease transmission. Continuous innovation in rapid testing technologies and expanding public health preparedness initiatives are expected to drive sustained growth across this application segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Prescription | OTC Testing, Prescription-based Testing | OTC Testing | OTC Testing |
| End-use | Hospitals, Diagnostic Centers, Research Laboratories, Home-care Settings, Others | Diagnostic Centers | Home-care Settings |
| Application | Cardio Metabolic Testing, Infectious Disease Testing, Nephrology Testing, Drug-of-abuse (DoA) Testing, Blood Glucose Testing, Pregnancy Testing, Cancer Biomarker Testing, Others | Cardio Metabolic Testing | Infectious Disease Testing |
| Technology | Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays, Agglutination Assays, Flow-through, Solid Phase, Biosensors | Lateral Flow Assays | Molecular Diagnostics |
| Product | Glucose Monitoring, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy and Fertility Testing Products, Tumor/cancer Marker Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drug-of-abuse (DoA) Testing Products, Fecal Occult Testing Products, Urinalysis Testing Products, Others | Glucose Monitoring | Infectious Disease Testing Products |
Competitive Landscape and Market Positioning
Leading companies in the point-of-care testing (POCT) market:
- Abbott Laboratories (United States)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Siemens Healthineers AG (Germany)
- Danaher Corporation (United States)
- Becton Dickinson and Company (United States)
- bioMérieux SA (France)
- Bio-Rad Laboratories, Inc. (United States)
- Sysmex Corporation (Japan)
- QuidelOrtho Corporation (United States)
- Nova Biomedical Corporation (United States)
Rapid decentralization of diagnostic services is reshaping the point-of-care testing market, encouraging manufacturers to compete on clinical accuracy while delivering faster, more intuitive testing platforms suitable for diverse care environments. Innovation is increasingly focused on integrating digital connectivity, automated workflows, and simplified sample handling to reduce operational complexity for healthcare professionals. The competitive environment is also expanding beyond traditional clinical settings as demand grows for accessible diagnostics in community healthcare, home-based monitoring, and emergency care. Suppliers capable of combining dependable analytical performance with scalable manufacturing, regulatory readiness, and seamless data integration are gaining strategic advantages as diagnostic decision-making becomes more distributed.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| bioMérieux SA (France) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Sysmex Corporation (Japan) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| Nova Biomedical Corporation (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Obdu Digital Health Care Private Limited | Jun-26 | Obdu Digital Health Care Private Limited implemented its National Operations & Compliance Policy 2026 under the Digital Doctor Clinic initiative. The framework establishes the operational protocols required to scale digital medical infrastructure and rural point-of-care testing services across India. |
| Fortis Hospital, Mulund | Feb-26 | Fortis Hospital, Mulund integrated bedside diagnostics, advanced point-of-care testing infrastructure, and digital clinical workflows into its new emergency department. The deployment demonstrates institutional adoption of POCT to accelerate clinical decision-making during critical care windows. |
| HLB Panagene | Jan-26 | HLB Panagene secured a cooperation agreement with RocGene Technology, obtaining exclusive domestic sales rights for RocGene's point-of-care testing product line. This distribution expansion directly scales HLB Panagene's commercial footprint in the competitive in vitro diagnostics sector. |
| Sciverse | Nov-25 | Sciverse entered a strategic collaboration with Bhat Biotech to co-develop next-generation molecular diagnostics. The partnership aims to enhance technological capabilities in advanced diagnostic platforms, with direct implications for point-of-care testing application development. |
| Noul | Jun-25 | Noul completed multicenter pilot studies validating its AI-powered miLab diagnostic platform for malaria and blood analysis. The positive clinical performance demonstrates the scalability and commercial readiness of the company's automated, intelligence-driven point-of-care testing technology. |
| HemoCue | Feb-24 | HemoCue, a Danaher subsidiary, established a strategic partnership with Novo Nordisk focused on expanding point-of-care testing infrastructure for pediatric type 1 diabetes. The collaboration targets underserved regions and low- and middle-income countries to improve early disease detection and management capabilities. |
| Roche | Dec-23 | Roche acquired LumiraDx's point-of-care diagnostic platform, strategically expanding its rapid testing capabilities. The transaction enhances Roche's decentralized diagnostic portfolio, allowing the company to deliver accelerated and more reliable testing solutions for various infectious diseases across global healthcare channels. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Point-of-Care Testing (POCT) Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Urine, Saliva, Nasal & Respiratory Samples, Other Specimen Types |
| Test Complexity | Simple & Rapid Tests, Moderate-complexity Tests, High-complexity Tests |
| Connectivity & Data Management | Standalone Systems, Network-connected Systems, Cloud-enabled Systems |
Point-of-Care Testing (POCT) Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Decentralized Care Adoption Roadmap |
|
| POCT Reimbursement & Procurement Economics |
|
| Connected Diagnostics & Data Integration |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of point-of-care testing (POCT)?
How much is the point-of-care testing industry expected to grow by 2036?
Why is decentralized healthcare driving growth in the point-of-care testing market?
How are portable biosensor technologies strengthening the point-of-care testing market?
Why does OTC testing lead the point-of-care testing market?
Which application segment is growing the fastest in the point-of-care testing market?
What makes North America the largest POCT market?
Why is Asia Pacific expected to see the fastest POCT market growth?
Which companies dominate the point-of-care testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization